Several antimalarial drugs have been used in the past with a reduction in the sensitivity of these parasites to these antimalarial drugs. The most potent antimalarial agents are the artemisinin-based combination therapies (ACTs), however, with reports of potential resistance to ACTs, there are great concerns among researchers in the field of drug design for potent antimalarial agents against the drug-resistant strains of Plasmodium. Although artemisinin-based combination therapies (ACTs) remain the first line of defense against malaria, backup or alternatives are needed to handle ACTs drug resistance strains by these parasites .